Promoter & FIIs Increase Stake: Kovai Medical Center & Hospital Launched Neuro Sciences & OPD Block and PG Institute
DSIJ Intelligence-1Categories: Mindshare, Trending
The company has a market capitalisation of Rs 5,995 crore with a PE of 26x, an ROE of 21 per cent and an ROCE of 23 per cent.
Kovai Medical Center and Hospital Limited (KMCH) has announced a significant expansion at its Coimbatore campus with the launch of the KMCH Institute of Neuro Sciences & OPD Block and the KMCH Medical College Post Graduate Institute, effective January 15, 2026. This new facility is designed to enhance the hospital's specialised care capabilities, featuring ultra-modern surgical theatres, dedicated neuro ICUs, and advanced departments for Master Health Checkups. The project, valued at approximately Rs 120 crore, is funded through a combination of internal accruals and Bank borrowings.
The expansion focuses on augmenting the hospital's infrastructure rather than just bed count, specifically targeting outpatient services and critical care for brain, spine, and nerve health. While KMCH maintained an existing capacity of 2,086 beds with a 60 per cent occupancy rate as of December 2025, this new addition aims to streamline patient flow and modernise surgical interventions. The full integration of these proposed capacities is expected to be completed over the next three months, marking a new phase for the institution's clinical reach in specialised medicine.
About the Company
Kovai Medical Center and Hospital Limited (KMCH) is a leading multispecialty healthcare provider based in Coimbatore, Tamil Nadu, that has evolved from a 250-bed facility in 1990 to a major medical hub with over 2,000 beds as of 2026. The institution is recognised for its comprehensive tertiary care, particularly in specialised fields such as cardiology, neurology, and multi-organ transplants, serving patients across Western Tamil Nadu and Kerala. Beyond clinical services, KMCH has established a strong presence in medical education through its KMCH Institute of Health Sciences and Research, and it continues to modernise its infrastructure.
The company has a market capitalisation of Rs 5,995 crore with a PE of 26x, an ROE of 21 per cent and an ROCE of 23 per cent. In Q3FY26, Promoter increased its stake to 56.53 per cent and FIIs bought 7,247 shares to increase their stake to 1.31 per cent compared to Q2FY26. The stock is up by 16.4 per cent from its 52-week low of Rs 4,810.20 per share and has given multibagger returns of 375 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.